NEW YORK, March 8, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Boston Scientific Corporation (NYSE: BSX), Thermo Fisher Scientific Inc. (NYSE: TMO), Volcano Corporation (NASDAQ: VOLC), Align Technology, Inc. (NASDAQ: ALGN) and Accuray Incorporated (NASDAQ: ARAY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Boston Scientific Corporation Research Report
Boston Scientific is scheduled to present PREVAIL clinical trial results on March 9, 2013 at the American College of Cardiology 2013 Annual Scientific Sessions. The study was designed to see if the company's WATCHMAN device could effectively prevent strokes. The WATCHMAN has already been available for sale in Europe since 2005 and some countries in Asia since 2009. In the United States, however, WATCHMAN is still an investigational device, and results from the PREVAIL confirmatory study are expected to be submitted for approval to the US FDA. WATCHMAN is a highly promising device for Boston Scientific, with Wells Fargo analyst Biegelsen projecting its sales to total at $159 by 2017. Going forward, Boston Scientific plans on outpacing its rivals and boost its business in high growth markets like endoscopy, urology, and women's health. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/b465_BSX]
Thermo Fisher Scientific Inc. Research Report
Thermo Fischer recently launched the Brilliance GBS Agar for the testing of Group B streptococci (GBS) during pregnancy. The new product is designed to simplify screening tests for clinicians and produce more accurate results. GBS is a bacterium that can be passed from mother to baby during labor, and is the most common cause of severe, sometimes fatal, infections. The product is designed for laboratories that are already screening for GBS but are looking for more efficient ways to produce results. Going forward, Thermo Fisher plans to continue investing in new products and emerging markets to drive growth. The company's One Lambda acquisition may also accelerate its growth in the transplant diagnostics market. The Full Research Report on Thermo Fisher Scientific Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/ce54_TMO]
Volcano Corporation Research Report
Volcano Corporation recently reported record fourth quarter revenue of $102.5 million, up 10 percent on a reported basis and up 12 percent on a constant currency basis. The company cites strength in its Fractional Flow Reserve disposable business as the reason for this increase. Going forward, the company's acquisitions of Sync-RX and Crux Biomedical are expected to help the company move beyond intravascular imaging to a wide variety of diagnostic and therapeutic solutions for both coronary and peripheral applications. These business expansion strategies may drive growth for the company. Furthermore, the company's market-leading position in Japan remains encouraging. The Full Research Report on Volcano Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/6ba1_VOLC]
Align Technology, Inc. Research Report
Last year, Align Technology's Invisalign Clear Aligner proved its worth, with Invisalign Clear Aligner case shipments totaling 365.5 thousand, up 17.5 percent year-over-year. This year, the company is working to push Invisalign's potential further. By appointing Julie Tay as Vice President for its Asia Pacific operations, the company may now execute its strategy of moving its four largest country markets (Australia, New Zealand, Hong Kong and Singapore) from an indirect selling business model to a direct selling business model. Align Technology recognizes that Asia Pacific may provide significant growth opportunities for the company, and this effort may help it to further accelerate its growth in the region. Seeing the company's positive momentum, analysts at Stifel Nicolaus raised their price target on the shares of the company from $32 to $38 and maintained their Buy rating. The Full Research Report on Align Technology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/9b76_ALGN]
Accuray Incorporated Research Report
At present, Accuray is setting up a cost structure that will enhance marketing capabilities and overall business processes to boost sales. The company's two new products, the CyberKnife and TomoTherapy devices, are the ones that are expected to benefit from this strategy. The company is also reducing its operating expenses to achieve sustainable profitability. To signal his confidence in the company, President and CEO of Accuray Inc. Joshua Levine recently bought 100,000 shares of Accuray Incorporated. Accuray's efforts to market its most valuable products may drive sales and allow the company to generate greater revenue in the future. The Full Research Report on Accuray Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/cb33_ARAY]
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers